Baiyunshan (00874.HK): Children's Xiaochaihu Granules Enter Phase II Clinical Trials.

Zhtng Cijng APP Newsletter, Baiyunshan (00874.HK) announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd. ("Guanghua Pharmaceutical"), has recently disclosed the registration information for the Phase II clinical trial of the children's Xiao Chaihu Granules developed by the company in the National Medical Products Administration's Drug Clinical Trial Registration and Information Disclosure Platform. The trial's professional title is "A randomized, double-blind, parallel-controlled, multicenter Phase II clinical study on the efficacy and safety of Xiao Chaihu Granules in treating children with gastroenteritis due to invasion of Shaoyang meridian in children".